ClinicalTrials.gg
Status unknownNCT02555800Updated Jul 26, 2016

Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis

A Phase 2 interventional study of Bevacizumab and Cidofovir in Recurrent Respiratory Papillomatosis, sponsored by Centro de Investigación en. Enfermedades Infecciosas, Mexico. Status unknown at 1 site in Mexico. Per ClinicalTrials.gov, last updated 2016-07-26.

Sponsored by Centro de Investigación en. Enfermedades Infecciosas, Mexico · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Sex
All
01

Study summary

The aim of this study is to compare the efficacy of intralesional bevacizumab, a monoclonal antibody against vascular endothelial growth factor, versus the antiviral drug cidofovir in patients with recurrent respiratory papillomatosis.

Read the detailed description

The investigators designed a randomized, double-blind, placebo-controlled study. Children and adults will be randomized to receive either 3 dosis of intralesional bevacizumab, cidofovir or saline solution. Primary endpoints are the assessment of changes in the annual surgery rate and Derkay papilloma severity grading scale; secondary endpoints are changes in the Voice Handicap Index and safety.

02

Conditions studied

  • Recurrent Respiratory Papillomatosis

Keywords

  • Laryngeal papillomatosis
  • Cidofovir
  • Bevacizumab
  • Recurrent respiratory papillomatosis
03

In context

Recurrent respiratory papillomatosis

32 studies on the registry are indexed under Recurrent respiratory papillomatosis; 9 are open to participants now.

This study's planned enrollment of 36 is above the median of 27 across 23 interventional studies indexed under Recurrent respiratory papillomatosis.

Browse Recurrent respiratory papillomatosis studies →

Lead sponsor

Centro de Investigación en. Enfermedades Infecciosas, Mexico is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with recurrent respiratory papillomatosis proven by .
  • Patients with 2 or more previous surgeries for papillomatosis

Exclusion criteria

Exclusion Criteria:

  • Patients with heart or renal disease
  • Patients who receive another therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Bevacizumab

    Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.

    Drug: Bevacizumab

  • Experimental
    Cidofovir

    Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.

    Drug: Cidofovir

  • Placebo comparator
    Saline

    Patients will receive 3 intralesional injections of 3.5 mL of saline solution every 3 to 6 weeks in a submucosal plane after surgical debulking.

    Other: Placebo

Interventions

  • Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.

    Also known as: Avastin

  • Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.

    Also known as: Vistide

  • OtherPlacebo

    Saline solution

06

What researchers measure

Primary outcomes

  1. Changes in the annual surgery rate

    Changes in the annual surgery rate before and after intervention

    Time frame: 12 months

  2. Severity of airway affection measured by the Derkay papilloma severity grading scale

    Changes in the Derkay papilloma severity grading scale before and after intervention

    Time frame: 12 months

Secondary outcomes

  1. Hoarseness severity measured by the Voice Handicap Index

    Changes in the Voice Handicap Index before and after intervention

    Time frame: 12 months

  2. Number of Treatment-Related Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE)

    Adverse events

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Centro de Investigacion en Enfermedades Infecciosas
    Mexico, 14080, Mexico
    Recruiting
    • Gustavo Reyes-Teran, M.D. · Contact+52(55)56667985
    • Yuria Ablanedo-Terrazas, M.D. · Contact+52(55)56667985
    • Gustavo Reyes-Teran, M.D. · Principal investigator
    • Yuria Ablanedo-Terrazas, M.D. · Sub investigator
    • Arturo Ramírez-García, M.D. · Sub investigator
    • Oscar Estrada-Camacho, M.D. · Sub investigator
    • Gabriel Tona-Acedo, M.D. · Sub investigator
08

References and documents

Publications

  • Ablanedo-Terrazas Y, Estrada-Camacho O, Alvarado-de la Barrera C, Ramirez-Garcia A, Tona-Acedo G, Bross-Soriano D, Schimelmitz-Idi J. Efficacy of cidofovir versus bevacizumab in recurrent respiratory papillomatosis: A randomized, double-blind, placebo-controlled pilot study. Acta Otorrinolaringol Esp (Engl Ed). 2022 Mar-Apr;73(2):82-88. doi: 10.1016/j.otoeng.2020.12.001. PubMed 35397828 ↗
  • Ablanedo-Terrazas Y, Estrada-Camacho O, Alvarado-de la Barrera C, Ramirez-Garcia A, Tona-Acedo G, Bross-Soriano D, Schimelmitz-Idi J. Efficacy of cidofovir versus bevacizumab in recurrent respiratory papillomatosis: A randomized, double-blind, placebo-controlled pilot study. Acta Otorrinolaringol Esp (Engl Ed). 2021 Jun 18:S0001-6519(21)00030-3. doi: 10.1016/j.otorri.2020.12.001. Online ahead of print. English, Spanish. PubMed 34154795 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Dec 2016 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2015
First posted
Sep 22, 2015
Start
Dec 2014
Primary completionEst.
Dec 2016
CompletionEst.
Jun 2017
Last update
Jul 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02555800
Lead sponsor
Centro de Investigación en. Enfermedades Infecciosas, Mexico
Responsible party
Gustavo Reyes-Teran (M.D., Centro de Investigación en. Enfermedades Infecciosas, Mexico) — Principal investigator
First posted
Sep 22, 2015
Start date
Dec 2014
Primary completion
Dec 2016 (estimated)
Completion
Jun 2017 (estimated)
Last update
Jul 26, 2016

Study contacts

Yuria Ablanedo-Terrazas, M.D.
Contact
yuria.ablanedo@cieni.org.mx
+525556667985
Gustavo Reyes-Terán, M.D.
principal investigator · Centro de Investigación en. Enfermedades Infecciosas, Mexico

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Cidofovir

Start the discussion